Future Challenge for Molecular Diagnostics Companies Will Be to Generate Profits While Forming Cooperative Relationships.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c27045) has announced the addition of Molecular Diagnostics: New Growth, New Markets to their offering. Molecular Diagnostics: New Growth, New Markets highlights current trends in the molecular diagnostic industry and the major prospects and challenges ahead. Advancing technologies are pushing the diagnostics industry to the fore, and the molecular diagnostics industry in particular is emerging as a powerful health care player with tremendous potential. Advances in PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) (polymerase chain reaction polymerase chain reaction (pŏl`ĭmərās') (PCR), laboratory process in which a particular DNA segment from a mixture of DNA chains is rapidly replicated, producing a large, readily analyzed sample of a piece of DNA; the process is ), multiplexing multiplexing, in communication, technique whereby two or more independent messages, or information-bearing signals, are carried by a single common medium, or channel. , sequencing, and other technologies are propelling both new and old companies forward with novel capabilities. The molecular diagnostic industry is characterized by a very diverse, constantly changing technology base that continuously produces new opportunities and applications. Similarly, a growing understanding of the molecular basis of cancer and other chronic diseases is opening up new realms of medicine to the possibilities of molecular diagnostic testing Diagnostic testing Testing performed to determine if someone is affected with a particular disease. Mentioned in: Von Willebrand Disease . While the infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. sector, particularly viral load testing Viral load test A new blood test for monitoring the speed of HIV replication in AIDS patients. The viral load test is based on PCR techniques and supplements the CD4+ cell count tests. , will continue to occupy the largest sector of the molecular diagnostics market, other areas, particularly oncology, will see greater rates of growth in the near future. Molecular Diagnostics: New Growth, New Markets offers a comprehensive evaluation of this dynamic market. Highlights include the following: -- A historical overview of molecular diagnostics, an analysis of the role of diagnostics in the growing field of personalized medicine  The external links in this article or section may require cleanup to comply with Wikipedia's content policies. , and a summary of major market trends and drivers. -- A review of the dominant and emerging applications of molecular diagnostics, with a focus on major areas of robust growth. Although PCR is the most important molecular diagnostic technology, there are other dominant techniques generating considerable profits. The report identifies and evaluates the tremendous opportunities in the marketplace for new, improved technologies. -- An assessment of the industry-landscape in terms of key non-technological trends and challenges, with a focus on regulation, consumer and health care provider education and marketing, and reimbursement. -- An evaluation of the emergence and growth of personalized per·son·al·ize tr.v. per·son·al·ized, per·son·al·iz·ing, per·son·al·iz·es 1. To take (a general remark or characterization) in a personal manner. 2. To attribute human or personal qualities to; personify. , or pharmacogenomic, medicine, which is providing tremendous revenue opportunities for molecular diagnostics. The challenge for molecular diagnostics companies will be to generate profits while forming cooperative relationships with pharma, regulatory agencies regulatory agency Independent government commission charged by the legislature with setting and enforcing standards for specific industries in the private sector. The concept was invented by the U.S. , consumers, and other stakeholders Stakeholders All parties that have an interest, financial or otherwise, in a firm-stockholders, creditors, bondholders, employees, customers, management, the community, and the government. in ways that facilitate drug-diagnostic co-development and end in a win-win-win situation for all parties. -- An examination of molecular diagnostic business models in the context of factors that are expected to drive the industry forward. -- Profiles of a select list and description of companies that have shown remarkable progress in the field, smaller companies that are expected to emerge as dominant players in particular content or technological areas, and companies that exemplify a noteworthy aspect of molecular diagnostic business. Companies Mentioned: -- Digene Corporation -- Genaissance Pharmaceuticals, Inc. -- MetriGenix Corporation -- Monogram monogram [Gr.,=single letter], symbol of a name or names, consisting typically of a letter or several letters worked together. A famous monogram is that of Christ, consisting of X (chi) and P (rho), the first two letters of Christ in Greek. Biosciences -- Orchid Cellmark -- Orion Genomics -- SEQUENOM, Inc. -- Solexa, Inc. -- Stratagene -- Third Wave Technologies, Inc. Chapters Include: Chapter 1. Introduction Chapter 2. The Technological Landscape Chapter 3. Molecular Diagnostics Applications Chapter 4. The Molecular Diagnostic Landscape: Obstacles Ahead Chapter 5. The Business of Molecular Diagnostics Chapter 6. Expert Interviews Chapter 7. Selected Company Profiles References Glossary Index Tables & Figures For more information visit http://www.researchandmarkets.com/reports/c27045 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion